专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010077061A3 PHARMACEUTICAL FORMULATIONS CONTAINING ANTIVIRAL DRUGS 审中-公开
标题翻译：含有抗病毒药物的药物制剂
公开(公告)号：WO2010077061A3
公开(公告)日：2010-11-04
申请号：PCT/KR2009007880
申请日：2009-12-29
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
IPC分类号： A61K31/70 , A61K9/22 , A61K31/513 , A61K47/30 , A61K47/38 , A61K47/42 , A61P31/12
CPC分类号： A61K31/513 , A61K31/70 , A61K47/38 , A61K47/42
摘要： The present invention relates to pharmaceutical formulations containing antiviral drugs and sustained-release materials, and to pharmaceutical formulations having an immediate release compartment containing drugs associated with cytochrome P450, as well as an extended release compartment containing antiviral drugs and sustained-release materials. The formulations of the present invention reduce interactions between antiviral drugs to increase the effects of the drugs and to decrease side effects.
摘要翻译：本发明涉及含有抗病毒药物和缓释材料的药物制剂，以及具有含细胞色素P450相关药物的速释隔室的药物制剂，以及含有抗病毒药物和缓释材料的缓释隔室。本发明的制剂减少抗病毒药物之间的相互作用以增加药物的作用并减少副作用。

2. 发明申请

WO2010098627A3 PHARMACEUTICAL PREPARATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2010098627A3
公开(公告)日：2011-01-06
申请号：PCT/KR2010001246
申请日：2010-02-26
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE AH RAM , JANG SEOK YOUNG , PARK YUN SANG , LEE NAYOUNG , LEE EUNMI
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE AH RAM , JANG SEOK YOUNG , PARK YUN SANG , LEE NAYOUNG , LEE EUNMI
IPC分类号： A61K9/22 , A61K9/20 , A61K47/30 , A61P35/00
CPC分类号： A61K9/209 , A61K31/436 , A61K31/4706 , A61K31/505 , A61K31/7068 , A61K2300/00
摘要： The present invention relates to a pharmaceutical preparation comprising an immediate-release compartment and an extended-release compartment, wherein said immediate-release compartment and said extended-release compartment each contain different oral anticancer drugs as active ingredients. The pharmaceutical preparation of the present invention is advantageous in that drug interactions and side effects of oral anticancer drugs can be minimized, and the administration of the pharmaceutical preparation can be easily performed.
摘要翻译：本发明涉及包含立即释放室和延长释放室的药物制剂，其中所述立即释放室和所述延长释放室各自含有不同的口服抗癌药物作为活性成分。本发明的药物制剂的优点在于能够使口服抗癌药物的药物相互作用和副作用最小化，能容易地进行药物制剂的给药。

3. 发明申请

WO2010077096A3 DRUG DELIVERY SYSTEM 审中-公开
标题翻译：药物输送系统
公开(公告)号：WO2010077096A3
公开(公告)日：2010-11-25
申请号：PCT/KR2009007968
申请日：2009-12-30
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
IPC分类号： A61J3/06 , A61J3/00
CPC分类号： A61J3/071 , A61M31/002
摘要： The present invention relates to a drug delivery system comprising: a plastic soft capsule having an enclosed space defined therein; a tablet to be kept in the interior space of the capsule; and a drug filling portion, wherein part of the tablet's surface is adhered closely to the inside surface of the capsule and the drug filling portion is composed of the remaining area of the interior space excluding the space occupied by the tablet. Examples of benefits of a drug delivery system according to the present invention include a system which is capable of controlling drug release, physically separating and then filling the same or different active ingredients contained in the system to prevent chemical reactions induced by physical blending of those ingredients, preventing interaction between drugs that can occur inside the body when different kinds of drugs are co-administered, and storing a large amount of active ingredients.
摘要翻译：药物输送系统技术领域本发明涉及一种药物输送系统，其包括：塑料软胶囊，其中限定有封闭空间; 将片剂保存在胶囊的内部空间中; 和药物填充部分，其中片剂表面的一部分紧密地粘附到胶囊的内表面，并且药物填充部分由除了片剂占据的空间之外的内部空间的剩余区域组成。根据本发明的药物递送系统的益处的实例包括能够控制药物释放，物理分离然后填充系统中包含的相同或不同活性成分以防止由这些成分物理混合诱导的化学反应的系统，当联合施用不同种类的药物时，防止在体内可能发生的药物之间的相互作用，并且储存大量的活性成分。

4. 发明申请

WO2009134057A3 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER 审中-公开
标题翻译：含有血管紧张素II受体阻断剂的药物制剂
公开(公告)号：WO2009134057A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002225
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2081 , A61K9/2866 , A61K31/41 , A61K31/4178
摘要： The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.
摘要翻译：本发明提供含有血管紧张素-II受体阻断剂和作为药理活性成分的释放控制材料的药物制剂以及包含立即释放室和延长释放室的药物制剂。立即释放隔室含有作为预防和抑制肝炎的药理学活性成分的药剂，并且延长释放室具有血管紧张素-II受体阻断剂作为药理学活性成分。本发明的制剂使药物和临床上降低血压的效果最大化并且在服用制剂时预防并发症，有助于避免与由肝脏中的相同酶代谢的药物相互作用，并且预防和抑制药物的发生引起的药物长期引起的肝炎。

5. 发明申请

WO2009125987A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶钙通道阻断剂的缓释隔室和具有血管紧张素-2受体阻断剂的速释隔室的药物制剂。本发明提供了这样的药物制剂，其中二氢吡啶钙通道阻断剂和血管紧张素-2受体阻断剂分别包含在每个隔室中并且其释放受到控制。由于制剂的每个不同区室中所含的每种不同药物在不同时间释放，本发明的药物制剂使药物之间的拮抗作用和副作用最小化，并使药物的特定作用最大化。通过本发明的两种药物之间的特定组合的药物制剂与单独施用每种药物或简单联合施用药物相比，在治疗或预防疾病方面具有显着的良好效果。

6. 发明申请

WO2009134086A9 PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE 审中-公开
标题翻译：药物制剂治疗心血管疾病
公开(公告)号：WO2009134086A9
公开(公告)日：2010-03-11
申请号：PCT/KR2009002278
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Valsartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (5) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and an Iresartan-containing retarded release compartment, and (7) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Candesartan-containing retarded release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with a single medication or a simply combined medication.
摘要翻译：本发明提供了（1）释放控制的药物制剂，其包含含有辛伐他汀的早期释放隔室和含有氯沙坦的缓释隔室，（2）释放控制的药物制剂，其包含含有辛伐他汀的早期释放隔室和奥美沙坦（3）包含含有辛伐他汀的早期释放隔室和含有缬沙坦的缓释隔室的释放控制药物制剂，（4）包含含有辛伐他汀的早期释放隔室的释放控制药物制剂和（5）包含含有罗苏伐他汀的早期释放隔室和含有氯沙坦的缓释隔室的释放控制药物制剂，（6）包含含有瑞舒伐他汀的早期释放的释放控制药物制剂隔间（7）含有含瑞舒伐他汀的早释隔室和含坎地沙坦的缓释隔室的释放控制药物制剂。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化，并使药物的独特作用最大化，因为制剂中不同药物所含的不同药物以时间差异释放。通过两种药物的特定组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出显着优异的疾病治疗或预防效果。

7. 发明申请

WO2009134076A3 COMBINED COMPOSITION FOR CONTROLLED-RELEASE OF ANGIOTENSIN-II-RECEPTOR BLOCKER AND HMG-COA REDUCTASE INHIBITOR 审中-公开
标题翻译：用于控制释放血管紧张素II受体阻断剂和HMG-COA还原酶抑制剂的组合物
公开(公告)号：WO2009134076A3
公开(公告)日：2010-02-18
申请号：PCT/KR2009002256
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/26 , A61K47/00
CPC分类号： A61K45/06
摘要： The present invention relates to a controlled-release combination of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, in which each ingredient of the combination can be control-released at a specific rate based on the different in-vivo expressions of each ingredient. The present invention is a combined pharmaceutical composition which is effective for treatment of hypertension and prevention of complications in the medical complication known as the metabolic syndrome wherein diabetes, obesity, hyperlipidemia, coronary artery disease and the like, appear in combination, and to a preparation method thereof. More particularly, the present invention relates to a controlled-release drug delivery system for a combination of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor which releases the drugs at optimal rates for their in vivo absorption, maximizes effects and improves patient compliance.
摘要翻译：本发明涉及血管紧张素-II受体阻断剂和HMG-CoA还原酶抑制剂的控释组合，其中组合的每种成分可以基于不同的体内表达以特定的速率进行控制释放的每种成分。本发明是一种组合药物组合物，其有效治疗高血压，预防与已知的糖尿病，肥胖症，高脂血症，冠状动脉疾病等组合出现的代谢综合征的医疗并发症的并发症，以及制剂方法。更具体地，本发明涉及用于血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的组合的控释药物递送系统，其以最佳速率释放药物用于其体内吸收，使效果最大化并且改善患者依从性。

8. 发明申请

WO2009134056A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134056A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002224
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/26 , A61K47/00
CPC分类号： A61K9/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing hydrochlorothiazide as a pharmacologically active ingredient and an extended-release compartment containing losartan as a pharmacologically active ingredient. Since the formulation of the present invention can deliver hydrochlorothiazide and losartan at a specific rate at different times, it is very effective in treating hypertension and preventing complications, and has the effects of improving the adaptation rate of the patient, optimizing drug delivery time and reducing side effects.
摘要翻译：本发明提供了包含含有氢氯噻嗪作为药理活性成分的立即释放室和含有氯沙坦作为药理活性成分的延长释放室的药物制剂。由于本发明的制剂可以在不同时间以特定的速率递送氢氯噻嗪和氯沙坦，因此在治疗高血压和预防并发症方面非常有效，并且具有改善患者适应率，优化药物递送时间和减少副作用。

9. 发明申请

WO2009134079A9 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134079A9
公开(公告)日：2010-03-11
申请号：PCT/KR2009002261
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO , LEE YOUNG JOO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44 , A61K47/00
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Irbesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Valsartan-containing retard release compartment, (5) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Telmisartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (7) a release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and a Losartan-containing retarded release compartment, and (8) release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and an Irbesartan-containing retard release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含阿托伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含阿托伐他汀的早期释放隔室和厄贝沙坦的释放控制药物制剂（3）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含有奥美沙坦的缓释隔室，（4）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含缬沙坦的延迟释放隔室，（5）包含含阿托伐他汀的早期释放隔室和含替米沙坦的缓释隔室的释放控制药物制剂，（6）包含含阿托伐他汀的早期释放的释放控制药物制剂 COM （7）包含匹伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，和（8）包含匹伐他汀的释放控制药物制剂早泄室和含有厄贝沙坦的缓释隔室。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的具体组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出非常优异的治疗或预防疾病的效果。

10. 发明申请

WO2009134053A3 PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDE-BASED COMPOUND WITH CONTROLLED RELEASE AND ANGIOTENSIN-II-RECEPTOR BLOCKER 审中-公开
标题翻译：含有受控释放的二氧化硫化合物和血管紧张素II受体阻断剂的药物组合物
公开(公告)号：WO2009134053A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002219
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON
IPC分类号： A61K9/22 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/616
CPC分类号： A61K9/00
摘要： The present invention relates to a pharmaceutical composition in which release of a thiazide-based compound and angiotensin-II-receptor blocker is controlled, and to a combination preparation technique for the same. More particularly, the present invention relates to a preparation technique capable of maximizing pharmacological and clinical blood pressure control effects and complication preventive effects and significantly reducing side effects by administrating a release-controlled combination preparation rather than administrating a single preparation of thiazide-based compound and a single preparation of angiotensin-II-receptor blocker at the same time.
摘要翻译：本发明涉及一种其中控制了噻嗪类化合物和血管紧张素-II受体阻断剂释放的药物组合物及其组合制备技术。更具体地，本发明涉及一种能够通过施用释放控制的组合制剂而不是施用单一制剂的噻嗪类化合物而使药理学和临床血压控制效果和并发症预防效果最大化并显着降低副作用的制备技术，同时单次制备血管紧张素-II受体阻滞剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式